Your browser doesn't support javascript.
loading
Etiology of hormone receptor positive breast cancer differs by levels of histologic grade and proliferation.
Abubakar, Mustapha; Chang-Claude, Jenny; Ali, H Raza; Chatterjee, Nilanjan; Coulson, Penny; Daley, Frances; Blows, Fiona; Benitez, Javier; Milne, Roger L; Brenner, Hermann; Stegmaier, Christa; Mannermaa, Arto; Rudolph, Anja; Sinn, Peter; Couch, Fergus J; Devilee, Peter; Tollenaar, Rob A E M; Seynaeve, Caroline; Figueroa, Jonine; Lissowska, Jolanta; Hewitt, Stephen; Hooning, Maartje J; Hollestelle, Antoinette; Foekens, Renée; Koppert, Linetta B; Bolla, Manjeet K; Wang, Qin; Jones, Michael E; Schoemaker, Minouk J; Keeman, Renske; Easton, Douglas F; Swerdlow, Anthony J; Sherman, Mark E; Schmidt, Marjanka K; Pharoah, Paul D; Garcia-Closas, Montserrat.
Afiliação
  • Abubakar M; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD.
  • Chang-Claude J; Division of Genetics and Epidemiology, The Institute of Cancer Research, London, United Kingdom.
  • Ali HR; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Chatterjee N; University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Coulson P; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
  • Daley F; Department of Biostatistics, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD.
  • Blows F; Department of Oncology, School of Medicine, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD.
  • Benitez J; Division of Genetics and Epidemiology, The Institute of Cancer Research, London, United Kingdom.
  • Milne RL; Division of Breast Cancer Research, Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom.
  • Brenner H; Department of Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, United Kingdom.
  • Stegmaier C; Human Genetics Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Mannermaa A; Centro de Investigacion en Red de Enfermedades Raras (CIBERER), Valencia, Spain.
  • Rudolph A; Cancer Epidemiology Centre, Cancer Council Victoria, Melbourne, VIC, Australia.
  • Sinn P; Melbourne School of Population and Global Health, Centre for Epidemiology and Biostatistics, The University of Melbourne, Melbourne, VIC, Australia.
  • Couch FJ; Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Devilee P; Division of Preventive Oncology, German Cancer Research Center (DKFZ), and National Center for Tumor Diseases (NCT), Heidelberg, Germany.
  • Tollenaar RAEM; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Seynaeve C; Saarland Cancer Registry, Saarland, Germany.
  • Figueroa J; School of Medicine, Institute of Clinical Medicine, Pathology and Forensic Medicine, Cancer Center of Eastern Finland, University of Eastern Finland, Kuopio, Finland.
  • Lissowska J; Department of Clinical Pathology, Imaging Center, Kuopio University Hospital, Kuopio, Finland.
  • Hewitt S; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Hooning MJ; Department of Pathology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.
  • Hollestelle A; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.
  • Foekens R; Department of Human Genetics & Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands.
  • Koppert LB; Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands.
  • Bolla MK; Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh, Scotland, United Kingdom.
  • Wang Q; Department of Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland.
  • Jones ME; Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Rockville, MD.
  • Schoemaker MJ; Department of Medical Oncology, Family Cancer Clinic, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
  • Keeman R; Department of Medical Oncology, Family Cancer Clinic, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
  • Easton DF; Department of Medical Oncology, Family Cancer Clinic, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
  • Swerdlow AJ; Department of Surgical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
  • Sherman ME; Research Department, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
  • Schmidt MK; The Sir Peter MacCallum Department of Oncology University of Melbourne, Parkville, Melbourne, VIC, Australia.
  • Pharoah PD; Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, United Kingdom.
  • Garcia-Closas M; Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, United Kingdom.
Int J Cancer ; 143(4): 746-757, 2018 08 15.
Article em En | MEDLINE | ID: mdl-29492969
ABSTRACT
Limited epidemiological evidence suggests that the etiology of hormone receptor positive (HR+) breast cancer may differ by levels of histologic grade and proliferation. We pooled risk factor and pathology data on 5,905 HR+ breast cancer cases and 26,281 controls from 11 epidemiological studies. Proliferation was determined by centralized automated measures of KI67 in tissue microarrays. Odds ratios (OR), 95% confidence intervals (CI) and p-values for case-case and case-control comparisons for risk factors in relation to levels of grade and quartiles (Q1-Q4) of KI67 were estimated using polytomous logistic regression models. Case-case comparisons showed associations between nulliparity and high KI67 [OR (95% CI) for Q4 vs. Q1 = 1.54 (1.22, 1.95)]; obesity and high grade [grade 3 vs. 1 = 1.68 (1.31, 2.16)] and current use of combined hormone therapy (HT) and low grade [grade 3 vs. 1 = 0.27 (0.16, 0.44)] tumors. In case-control comparisons, nulliparity was associated with elevated risk of tumors with high but not low levels of proliferation [1.43 (1.14, 1.81) for KI67 Q4 vs. 0.83 (0.60, 1.14) for KI67 Q1]; obesity among women ≥50 years with high but not low grade tumors [1.55 (1.17, 2.06) for grade 3 vs. 0.88 (0.66, 1.16) for grade 1] and HT with low but not high grade tumors [3.07 (2.22, 4.23) for grade 1 vs. 0.85 (0.55, 1.30) for grade 3]. Menarcheal age and family history were similarly associated with HR+ tumors of different grade or KI67 levels. These findings provide insights into the etiologic heterogeneity of HR+ tumors.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Receptores de Progesterona / Receptores de Estrogênio / Proliferação de Células Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Receptores de Progesterona / Receptores de Estrogênio / Proliferação de Células Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Ano de publicação: 2018 Tipo de documento: Article